Cargando…

A Mass Spectrometry Imaging Based Approach for Prognosis Prediction in UICC Stage I/II Colon Cancer

SIMPLE SUMMARY: Tumor treatment is heavily dictated by the tumor progression status. However, in colon cancer, it is difficult to predict disease progression in the early stages. In this study, we have employed a proteomic analysis using matrix-assisted laser desorption/ionization mass spectrometry...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin, Benedikt, Gonçalves, Juliana P. L., Bollwein, Christine, Sommer, Florian, Schenkirsch, Gerhard, Jacob, Anne, Seibert, Armin, Weichert, Wilko, Märkl, Bruno, Schwamborn, Kristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582467/
https://www.ncbi.nlm.nih.gov/pubmed/34771536
http://dx.doi.org/10.3390/cancers13215371
_version_ 1784596993004273664
author Martin, Benedikt
Gonçalves, Juliana P. L.
Bollwein, Christine
Sommer, Florian
Schenkirsch, Gerhard
Jacob, Anne
Seibert, Armin
Weichert, Wilko
Märkl, Bruno
Schwamborn, Kristina
author_facet Martin, Benedikt
Gonçalves, Juliana P. L.
Bollwein, Christine
Sommer, Florian
Schenkirsch, Gerhard
Jacob, Anne
Seibert, Armin
Weichert, Wilko
Märkl, Bruno
Schwamborn, Kristina
author_sort Martin, Benedikt
collection PubMed
description SIMPLE SUMMARY: Tumor treatment is heavily dictated by the tumor progression status. However, in colon cancer, it is difficult to predict disease progression in the early stages. In this study, we have employed a proteomic analysis using matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI). MALDI-MSI is a technique that measures the molecular content of (tumor) tissue. We analyzed tumor samples of 276 patients. If the patients developed distant metastasis, they were considered to have a more aggressive tumor type than the patients that did not. In this comparative study, we have developed bioinformatics methods that can predict the tendency of tumor progression and advance a couple of molecules that could be used as prognostic markers of colon cancer. The prediction of tumor progression can help to choose a more adequate treatment for each individual patient. ABSTRACT: Currently, pathological evaluation of stage I/II colon cancer, following the Union Internationale Contre Le Cancer (UICC) guidelines, is insufficient to identify patients that would benefit from adjuvant treatment. In our study, we analyzed tissue samples from 276 patients with colon cancer utilizing mass spectrometry imaging. Two distinct approaches are herein presented for data processing and analysis. In one approach, four different machine learning algorithms were applied to predict the tendency to develop metastasis, which yielded accuracies over 90% for three of the models. In the other approach, 1007 m/z features were evaluated with regards to their prognostic capabilities, yielding two m/z features as promising prognostic markers. One feature was identified as a fragment from collagen (collagen 3A1), hinting that a higher collagen content within the tumor is associated with poorer outcomes. Identification of proteins that reflect changes in the tumor and its microenvironment could give a very much-needed prediction of a patient’s prognosis, and subsequently assist in the choice of a more adequate treatment.
format Online
Article
Text
id pubmed-8582467
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85824672021-11-12 A Mass Spectrometry Imaging Based Approach for Prognosis Prediction in UICC Stage I/II Colon Cancer Martin, Benedikt Gonçalves, Juliana P. L. Bollwein, Christine Sommer, Florian Schenkirsch, Gerhard Jacob, Anne Seibert, Armin Weichert, Wilko Märkl, Bruno Schwamborn, Kristina Cancers (Basel) Article SIMPLE SUMMARY: Tumor treatment is heavily dictated by the tumor progression status. However, in colon cancer, it is difficult to predict disease progression in the early stages. In this study, we have employed a proteomic analysis using matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI). MALDI-MSI is a technique that measures the molecular content of (tumor) tissue. We analyzed tumor samples of 276 patients. If the patients developed distant metastasis, they were considered to have a more aggressive tumor type than the patients that did not. In this comparative study, we have developed bioinformatics methods that can predict the tendency of tumor progression and advance a couple of molecules that could be used as prognostic markers of colon cancer. The prediction of tumor progression can help to choose a more adequate treatment for each individual patient. ABSTRACT: Currently, pathological evaluation of stage I/II colon cancer, following the Union Internationale Contre Le Cancer (UICC) guidelines, is insufficient to identify patients that would benefit from adjuvant treatment. In our study, we analyzed tissue samples from 276 patients with colon cancer utilizing mass spectrometry imaging. Two distinct approaches are herein presented for data processing and analysis. In one approach, four different machine learning algorithms were applied to predict the tendency to develop metastasis, which yielded accuracies over 90% for three of the models. In the other approach, 1007 m/z features were evaluated with regards to their prognostic capabilities, yielding two m/z features as promising prognostic markers. One feature was identified as a fragment from collagen (collagen 3A1), hinting that a higher collagen content within the tumor is associated with poorer outcomes. Identification of proteins that reflect changes in the tumor and its microenvironment could give a very much-needed prediction of a patient’s prognosis, and subsequently assist in the choice of a more adequate treatment. MDPI 2021-10-26 /pmc/articles/PMC8582467/ /pubmed/34771536 http://dx.doi.org/10.3390/cancers13215371 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Martin, Benedikt
Gonçalves, Juliana P. L.
Bollwein, Christine
Sommer, Florian
Schenkirsch, Gerhard
Jacob, Anne
Seibert, Armin
Weichert, Wilko
Märkl, Bruno
Schwamborn, Kristina
A Mass Spectrometry Imaging Based Approach for Prognosis Prediction in UICC Stage I/II Colon Cancer
title A Mass Spectrometry Imaging Based Approach for Prognosis Prediction in UICC Stage I/II Colon Cancer
title_full A Mass Spectrometry Imaging Based Approach for Prognosis Prediction in UICC Stage I/II Colon Cancer
title_fullStr A Mass Spectrometry Imaging Based Approach for Prognosis Prediction in UICC Stage I/II Colon Cancer
title_full_unstemmed A Mass Spectrometry Imaging Based Approach for Prognosis Prediction in UICC Stage I/II Colon Cancer
title_short A Mass Spectrometry Imaging Based Approach for Prognosis Prediction in UICC Stage I/II Colon Cancer
title_sort mass spectrometry imaging based approach for prognosis prediction in uicc stage i/ii colon cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582467/
https://www.ncbi.nlm.nih.gov/pubmed/34771536
http://dx.doi.org/10.3390/cancers13215371
work_keys_str_mv AT martinbenedikt amassspectrometryimagingbasedapproachforprognosispredictioninuiccstageiiicoloncancer
AT goncalvesjulianapl amassspectrometryimagingbasedapproachforprognosispredictioninuiccstageiiicoloncancer
AT bollweinchristine amassspectrometryimagingbasedapproachforprognosispredictioninuiccstageiiicoloncancer
AT sommerflorian amassspectrometryimagingbasedapproachforprognosispredictioninuiccstageiiicoloncancer
AT schenkirschgerhard amassspectrometryimagingbasedapproachforprognosispredictioninuiccstageiiicoloncancer
AT jacobanne amassspectrometryimagingbasedapproachforprognosispredictioninuiccstageiiicoloncancer
AT seibertarmin amassspectrometryimagingbasedapproachforprognosispredictioninuiccstageiiicoloncancer
AT weichertwilko amassspectrometryimagingbasedapproachforprognosispredictioninuiccstageiiicoloncancer
AT marklbruno amassspectrometryimagingbasedapproachforprognosispredictioninuiccstageiiicoloncancer
AT schwambornkristina amassspectrometryimagingbasedapproachforprognosispredictioninuiccstageiiicoloncancer
AT martinbenedikt massspectrometryimagingbasedapproachforprognosispredictioninuiccstageiiicoloncancer
AT goncalvesjulianapl massspectrometryimagingbasedapproachforprognosispredictioninuiccstageiiicoloncancer
AT bollweinchristine massspectrometryimagingbasedapproachforprognosispredictioninuiccstageiiicoloncancer
AT sommerflorian massspectrometryimagingbasedapproachforprognosispredictioninuiccstageiiicoloncancer
AT schenkirschgerhard massspectrometryimagingbasedapproachforprognosispredictioninuiccstageiiicoloncancer
AT jacobanne massspectrometryimagingbasedapproachforprognosispredictioninuiccstageiiicoloncancer
AT seibertarmin massspectrometryimagingbasedapproachforprognosispredictioninuiccstageiiicoloncancer
AT weichertwilko massspectrometryimagingbasedapproachforprognosispredictioninuiccstageiiicoloncancer
AT marklbruno massspectrometryimagingbasedapproachforprognosispredictioninuiccstageiiicoloncancer
AT schwambornkristina massspectrometryimagingbasedapproachforprognosispredictioninuiccstageiiicoloncancer